🔗 Share this article

While America continues making unprecedented revisions to its vaccine recommendations, an unexpected name appears somewhat surprisingly: Høeg, a US-based physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccines during the global health crisis and has concentrated on alleged deaths after COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Schedule

Health officials had intended to reveal sweeping changes to the childhood vaccination calendar in December, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US out of step with much of the world with little proof for public health gain. This reveal has been delayed until the new year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to run the division this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood immunization guidelines in the US to become more like Denmark's approach, a nation with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has no obvious background in medication creation, oversight or management, which has been typical for former directors of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and CBER since spring.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in industry regulation.”

Previous directors of the center would “understand regulatory frameworks and the science of drug development”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who led the center have had.”

CDER has an enormous range of responsibilities at the agency, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office clears numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those need to be managed,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership element to the role, which oversees in excess of 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries are based on inaccurate assumptions”.

“Her experience aligns with the duties of her position,” the representative stated, citing the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's recently launched expedited review system, a disputed rapid drug-approval program that reportedly troubled her predecessors. “By what process are these drugs being chosen for this voucher program? Who takes the decisions?” Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards laxer rules of most medications, aside from shots.”

Established History on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, track record, critics said. She released a research paper using non-validated volunteer-provided data to determine the frequency of myocarditis after COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the current government included altering rules for new vaccines and halting “unnecessary” immunizations, she said following the vote on a podcast. At the agency, Høeg has according to sources proposed barring teenage boys from getting Covid vaccines.

“She’s an all-around dogmatist who starts off with her conclusions and reverse-engineers to fit the science in a extremely misleading, dishonest manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|